Abstract:Piperine (PIP), the major alkaloid component from Piper longum L. and Piper nigrum L., could enhance the bioavailabilities of other drugs including rosuvastatin, peurarin and docetaxel (DOX) via inhibition of CYP3A and P-glycoprotein activity. Nevertheless, the effect of such drug combination usage on the in vivo exposure of PIP has not been investigated due to lack of assay for the simultaneous determination of PIP and other drugs such as DOX. Besides, the reported pharmacokinetics of PIP varied a lot without appropriate bioavailability determined from the same dose. In the current study, an LC/MS/MS method has been developed to simultaneously determine the plasma concentrations of PIP and DOX and further applied to investigate the pharmacokinetics properties of PIP after oral and intravenous administrations as well as the pharmacokinetics interactions between PIP and DOX after their co-administration. A simple protein precipitation method was employed for plasma sample treatment by adding a mixture of methanol and acetonitrile (1:1, v/v) with glibenclamide as internal standard (IS). The LC/MS/MS system consisted of Agilent 6430 series LC pumps and auto-sampler. The chromatographic separation was carried out in 15min on a Waters C18 column (150×3.9mm i.d., 4μm) with a mobile phase containing 0.2% formic acid and acetonitrile (1:1, v/v) at a flow rate of 0.4ml/min. The detection was performed using the positive ion electrospray ionization (ESI) in multiple reaction monitoring (MRM) mode with precursor-to-product ion transitions at m/z 286.1→201.1 for PIP, m/z 830.3→548.9 for DOX and m/z 494.2→369.0 for IS. The method demonstrated good linearity for both PIP and DOX over the concentration range of 2.5-1280ng/ml with LLOD at 2.5ng/ml. The intra-day and inter-day precisions were less than 13.34% and relative error (R.E.) representing accuracy was in the range of -11.38 to 3.15%. The recoveries of PIP, DOX and IS were above 75% and there was no matrix effect. PIP and DOX exhibited good stabilities under various conditions. PIP was administrated via intravenous bolus at 3.5mg/kg and via oral administration at 35mg/kg and 3.5mg/kg, while DOX was intravenously administrated at 7mg/kg to Sprague-Daley rats. The plasma concentrations of PIP and DOX were determined using the above developed and validated method. At the dose of 3.5mg/kg, the bioavailability of PIP was calculated to be 25.36%. Its AUC0→t was unproportionally increased with doses, indicating a potential non-linear pharmacokinetics profile of PIP. It was found that the AUC0→t and C0 of DOX and t1/2 of PIP were significantly increased after their combination use, suggesting potential enhanced bioavailability of not only DOX but also PIP, which may lead to the overall enhanced pharmacological effects.

Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.

Enhanced Anti-Tumor Efficacy and Mechanisms Associated with Docetaxel-Piperine Combination- in Vitro and in Vivo Investigation Using a Taxane-Resistant Prostate Cancer Model.

Pharmacokinetic Effects of Curcumin on Docetaxel Mediated by OATP1B1, OATP1B3 and CYP450s

Cytochrome P450 3A Selectively Affects the Pharmacokinetic Interaction Between Erlotinib and Docetaxel in Rats.

Non-linear Pharmacokinetics of Piperine and Its Herb-Drug Interactions with Docetaxel in Sprague-Dawley Rats.

Antitumor and radiosensitizing effect of docetaxel on human hepatocellular carcinoma and its mechanisim in vivo

A Multicenter, Randomized Clinical Trial Comparing The Three-Weekly Docetaxel Regimen Plus Prednisone Versus Mitoxantone Plus Prednisone For Chinese Patients With Metastatic Castration Refractory Prostate Cancer

The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism

Pharmacokinetic Properties of Wogonin and Its Herb-Drug Interactions with Docetaxel in Rats with Mammary Tumors.

The Anti-Tumor Activity Of Zoledronic Acid And Synergistic Effect Of Zoledronic Acid Combination With Docetaxel On Prostate Cancer Cell Line Pc-3 In Vitro At Clinically Achievable Concentrations

Effect of docetaxel on expression of eIF3a in human lung cancer A549 cell line

Influence of Tripterygium Glycosides Tablets on Cytochrome CYP2E1 and CYP3A4 Activities in Rats

Effects of cytochrome P4503A inducer dexamethasone on the metabolism and toxicity of triptolide in rat.

Pyrrolidine dithiocarbamate enhances chemosensitivity of ovarian cancer cells to docetaxel and its machanism

Enhanced oral bioavailability of docetaxel in rats combined with myricetin: In situ and in vivo evidences.

Investigation on pharmacokinetics, tissue distribution and excretion of 1-triacontanol in rats by gas chromatography-tandem mass spectrometry (GC-MS/MS).

The Effects of Matrine in Combination with Docetaxel on Castration-Resistant (Androgen-Independent) Prostate Cancer.

A Robust LC-MS/MS Method for the Simultaneous Determination of Docetaxel and Voriconazole in Rat Plasma and Its Application to Pharmacokinetic Studies.

The Role of Testicular Nuclear Receptor 4 in Chemo-Resistance of Docetaxel in Castration-Resistant Prostate Cancer.

Analysis of the Effect of Trastuzumab Combined with Docetaxel on Serum Tumor Markers in the Treatment of HER-2 Positive Breast Cancer and Factors Influencing Therapeutic Efficacy

Effect of PI3K/Akt Signal Pathway Inhibitor on Docetaxel Nanoparticles in Cell Uptake, Cell Colony, Caspase-3 & Caspase-9 Expression and Pharmacokinetics